Combined Effect of Transfusion and Blood Groups on the Survival of Patients With Breast Cancer. A Clinical Study of 901 Patients †

Previous reports by the authors and by others have shown that trans fusion adversely affects the survival of cancer patients. To delineate fur ther the mechanism of action of blood transfusion on biological behavior of cancer, the authors studied the role of the major blood groups ABO in 901 patients who had all undergone radi cal surgery for operable primary breast cancer and among whom 294 had received at least one unit of whole blood perioperatively. Multivariate analysis using Cox's regression models on life tables was used. It was found that the adverse effect of transfusion on survival was a blood group-related phenomenon manifesting its action in patients with blood groups A and B (P = 0.0006 and P = 0.006 respectively). The most im pressive effect of transfusion was seen in patients whose age was be tween forty-one and fifty (51.9% ten- year actuarial survival in 47 transfused patients compared with 73.9% in 70 nontransfused ones). A hypothesis is presented suggest ing that transfusion exerts its effect on the hemostatic system, promoting clotting in group A and B patients and fibrinolysis in group O and AB patients, and thus affects metastatic cascade, with results that have been presented in this series.

[1]  C. V. D. van de Velde,et al.  Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients , 1987, Cancer.

[2]  M. Agarwal,et al.  Association between transfusion of whole blood and recurrence of cancer. , 1986, British medical journal.

[3]  S. Rosenberg,et al.  Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Tartter,et al.  Perioperative blood transfusion adversely affects prognosis after resection of Stage I (subset N0) non-oat cell lung cancer. , 1984, The Journal of thoracic and cardiovascular surgery.

[5]  R. Foster,et al.  Blood transfusions and survival after surgery for breast cancer. , 1984, Archives of surgery.

[6]  Weissman Dw.  Tumor origin, progression, immunogenicity, and immunotherapy. , 1984 .

[7]  A Morabito,et al.  Prognostic factors and risk groups: some results given by using an algorithm suitable for censored survival data. , 1983, Statistics in medicine.

[8]  P. Tartter,et al.  EFFECT OF BLOOD TRANSFUSIONS ON COLONIC MALIGNANCY RECURRENCE RATE , 1982, The Lancet.

[9]  O. Ringdén,et al.  Reduced immunologic responsiveness in multitransfused anemic nonuremic patients. , 1982, Transplantation proceedings.

[10]  G. Nicolson,et al.  Tumor metastasis is not due to adaptation of cells to a new organ environment. , 1982, Science.

[11]  M. R. Mickey,et al.  Blood transfusions and kidney transplants: remaining controversies. , 1981, Transplantation proceedings.

[12]  G. Coles,et al.  The effect of blood transfusion on T-suppressor cells in renal dialysis patients. , 1981, Transplantation proceedings.

[13]  I. Saporoschetz,et al.  Correlation Between Anergy and a Circulating Immunosuppressive Factor Following Major Surgical Trauma , 1979, Annals of surgery.

[14]  W. Moore,et al.  The Fibrinolytic System: A Key to Tumor Metastasis? , 1979, Annals of surgery.

[15]  P. Bore,et al.  Transfusion-induced renal allograft protection. , 1979, Transplantation proceedings.

[16]  T C Chalmers,et al.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. , 1978, The New England journal of medicine.

[17]  I. Fidler,et al.  Tumor heterogeneity and the biology of cancer invasion and metastasis. , 1978, Cancer research.

[18]  H. Saito,et al.  The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments. , 1978, The Journal of clinical investigation.

[19]  J. H. Roger,et al.  DIFFERENTIAL KIDNEY GRAFT SURVIVAL ASSOCIATED WITH INTERACTION BETWEEN RECIPIENT ABO GROUP AND PRETRANSPLANT BLOOD TRANSFUSION , 1977, Transplantation.

[20]  P. Terasaki,et al.  EFFECT OF BLOOD-GROUP ON RELATION BETWEEN HLA MATCH AND OUTCOME OF CADAVER KIDNEY TRANSPLANTS , 1977, The Lancet.

[21]  A. Kaplan,et al.  The Hageman factor dependent pathways of human plasma. , 1974, Microvascular research.

[22]  J. Unkeless,et al.  SECRETION OF PLASMINOGEN ACTIVATOR BY STIMULATED MACROPHAGES , 1974, The Journal of experimental medicine.

[23]  C. Forbes,et al.  Influence of ABO blood groups and fibrinogen on thrombus formation and aggregation of red cells in cardiovascular and malignant diseases: new aspects of biorheological characterization of disease. , 1973, Biorheology.

[24]  J. Griffiths,et al.  Fibrinolysis and circulating malignant cells. , 1973, Surgery, gynecology & obstetrics.

[25]  M. R. Mickey,et al.  Effect of blood transfusions on subsequent kidney transplants. , 1973, Transplantation proceedings.

[26]  U. Abildgaard,et al.  Antithrombin-III concentration and ABO blood-groups , 1971 .

[27]  G. Eklund,et al.  Oral contraceptives, venous thromboembolic disease, and ABO blood type. , 1971, Lancet.

[28]  M. Bates.  Venous thromboembolic disease and ABO blood type. , 1971, Lancet.

[29]  N. Loudon,et al.  Venous thromboembolic disease and ABO blood type. , 1969, Lancet.

[30]  O. Ratnoff,et al.  THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITOR , 1969, The Journal of experimental medicine.

[31]  R. Mcconnell,et al.  ABO blood groups in gastric bleeding. , 1966, Gut.

[32]  E. Cliffton,et al.  EFFECT OF INHIBITORS OF FIBRINOLYTIC ENZYMES ON DEVELOPMENT OF PULMONARY METASTASES. , 1964, Journal of the National Cancer Institute.

[33]  A. Barr,et al.  The Plasma Concentration of Factor VIII in the Normal Population , 1964, British journal of haematology.

[34]  J. Woods,et al.  AN IN VITRO STUDY OF FIBRINOLYTIC AGENTS ON V2 CARCINOMA CELLS AND INTRAVASCULAR THROMBI IN RABBITS. , 1963, Bulletin of the Johns Hopkins Hospital.

[35]  B. Fisher,et al.  Host factors influencing the development of metastases. , 1962, The Surgical clinics of North America.

[36]  E. Cliffton,et al.  Factors affecting the development of metastatic cancer. Effect of alterations in clotting mechanism , 1962, Cancer.

[37]  M. Melamed,et al.  The effect of human fibrinolysin on survival of carcinosarcoma 256 walker cells in the blood , 1961, Cancer.

[38]  E. Cliffton,et al.  Cancer cells in the blood in simulated colon cancer, resectable and unresectable: effect of fibrinolysin and heparin on growth potential. , 1961, Surgery.

[39]  H. Colten,et al.  Molecular immunobiology of complement biosynthesis: a model of single-cell control of effector-inhibitor balance. , 1986, Annual review of immunology.

[40]  J. Kovarik,et al.  Course of breast cancer disease and ABO blood groups. , 1985, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  L. Sandu.  Letter: Corticosteroids in Landry-Guillain-Barré-Strohl syndrome. , 1974, Lancet.

[42]  J. Ambrus,et al.  PROGESTATIONAL AGENTS AND BLOOD COAGULATION. , 1965, American journal of obstetrics and gynecology.

[43]  B. Boeryd.  Action of heparin and plasminogen inhibitor (EACA) on metastatic tumour spread in an isologous system. , 1965, Acta pathologica et microbiologica Scandinavica.

[44]  E. Cliffton,et al.  THE EFFECTS OF FIBRIN FORMATION AND ALTERATIONS IN THE CLOTTING MECHANISM ON THE DEVELOPMENT OF METASTASES. , 1965, Vascular diseases.